Intervention, interventional group characteristics, and duration of studies exploring the efficacy of SGLT-2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic fatty liver disease. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.